Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties

Kidney Int. 2020 Nov;98(5):1135-1148. doi: 10.1016/j.kint.2020.05.053. Epub 2020 Jul 3.

Abstract

In recent years, a substantial body of experimental and clinical work has been devoted to C3 glomerulopathy and Ig-mediated membranoproliferative glomerulonephritis. Despite the rapid accumulation of data, several uncertainties about these 2 rare forms of nephropathies persist. They concern their pathophysiology, classification, clinical course, relevance of biomarkers and of pathology findings, and assessment of the efficacy of the available therapies. The present review discusses the impact of these uncertainties on the clinical management of patients.

Keywords: C3 glomerulopathy; Ig-mediated membranoproliferative glomerulonephritis; complement.

Publication types

  • Review

MeSH terms

  • Complement C3
  • Glomerulonephritis, Membranoproliferative* / drug therapy
  • Humans
  • Kidney Diseases* / therapy

Substances

  • Complement C3